The surfaceome refers to the complete set of proteins expressed on the cell surface. In oncology, these proteins are critically important because they mediate how cancer cells interact with their environment — including immune surveillance, drug response, and metastasis. They are also the primary targets for antibody-drug conjugates (ADCs), CAR-T therapies, and radiopharmaceuticals. Understanding the true surfaceome enables more accurate target selection and more precise patient stratification.

Most publicly available datasets are derived from cell lines, which often fail to reflect the complexity and heterogeneity of real tumors. Champions’ dataset is built directly from human tumors, using a proprietary plasma membrane isolation protocol that eliminates intracellular contamination and enhances specificity. This approach yields clean, reproducible, and clinically relevant data that truly represents the tumor surface in advanced disease.

Our dataset originates from our living tumor bank, composed of advanced-stage, metastatic tumors collected from patients who have relapsed after standard treatments. These tumors preserve their native state and maintain the cellular heterogeneity critical for translational research.

Champions uses a biochemically validated method that fractionates tumor samples into surface, intracellular, and whole-cell proteomes. By quantifying each fraction in parallel, we can measure true protein enrichment at the cell surface — filtering out noise from lysed organelles or background contamination. This results in a high-fidelity view of surface protein expression.

Surface proteomics is integrated with Champions’ multiomic platform, including genomics, transcriptomics, and pharmacology. This allows researchers to correlate surface protein expression with genetic drivers, treatment response, and drug sensitivity — offering a more comprehensive view of tumor biology and actionable insights for drug development.

Yes. Qualified partners can request access to our secure Data Room, where they can explore sample datasets, protein enrichment metrics, and multiomic integration. This enables data teams to evaluate interpretability and relevance for their internal programs before engagement.

Champions’ cell surface proteomics dataset is used across the drug development pipeline to improve decision making and reduce risk. ADC and radiopharma teams use it to confirm that their chosen targets are truly expressed on human tumors before investing in costly preclinical or clinical programs. Pharma and biotech groups apply it to build more accurate biomarker hypotheses, stratify patients based on surface protein expression, and understand mechanisms of resistance that are invisible in traditional proteomic datasets. Investors and innovation arms rely on it to evaluate the translational relevance of pipeline targets, while AI companies integrate the data to train predictive models with richer, clinically grounded features.

By providing clinically validated expression data from real tumors, our dataset helps teams validate mechanisms of action, predict off-target effects, and select patients more precisely. This translates to better trial design, lower risk of failure, and more efficient resource allocation.

Yes. In addition to our existing dataset, Champions offers bespoke surface proteomics studies using client-specified models or indications. We can generate custom profiles, validate specific targets, and integrate findings with pharmacological studies or PDX models.

You can request access to the Data Room or schedule a consultation with our data science and translational oncology team by completing the contact form on this page or emailing data@championsoncology.com. We’ll guide you through the dataset, potential applications, and partnership options.